The HeartWare Ventricular Assist Device (HVAD): A Single Institutional 10-Year Experience.

Objectives: The aim of this study was to analyze our 10-year experience with the HVAD in a real-world scenario in a high-volume German heart center.

Methods: We retrospectively analyzed outcomes of adults (≥18 years) with terminal heart failure (HF), who underwent HVAD implantation for durable LVAD therapy in our center between October 2009 and March 2020. Primary and secondary end points were all-cause death after implantation and LVAD-associated complications, respectively.

Outcome of operated and unoperated adults with congenital cardiac disease lost to follow-up for more than five years.

Many patients with congenital cardiac disease need a regular cardiologic follow-up (FU) even after successful primary treatment. Nevertheless, many of them are lost to FU. The present study verifies for the first time the outcome of adults with congenital cardiac disease lost to FU of a specialized institution for >5 years.